SIMOLA, NICOLA
 Distribuzione geografica
Continente #
EU - Europa 173.899
NA - Nord America 9.828
AS - Asia 3.877
Continente sconosciuto - Info sul continente non disponibili 742
SA - Sud America 620
AF - Africa 100
OC - Oceania 9
Totale 189.075
Nazione #
IT - Italia 171.910
US - Stati Uniti d'America 9.666
SG - Singapore 1.492
CN - Cina 1.397
BR - Brasile 492
UA - Ucraina 487
SE - Svezia 450
VN - Vietnam 374
DE - Germania 244
FI - Finlandia 206
GB - Regno Unito 185
FR - Francia 173
HK - Hong Kong 151
IN - India 91
CA - Canada 71
KR - Corea 57
BD - Bangladesh 55
PL - Polonia 49
AR - Argentina 44
MX - Messico 40
NL - Olanda 36
IQ - Iraq 32
JP - Giappone 31
RU - Federazione Russa 29
ZA - Sudafrica 25
ID - Indonesia 23
PK - Pakistan 23
TR - Turchia 22
ES - Italia 21
CO - Colombia 18
MA - Marocco 18
EC - Ecuador 17
BE - Belgio 16
EG - Egitto 16
UZ - Uzbekistan 16
JM - Giamaica 15
VE - Venezuela 15
AT - Austria 14
CH - Svizzera 14
CL - Cile 14
SA - Arabia Saudita 13
PH - Filippine 12
CZ - Repubblica Ceca 11
NI - Nicaragua 10
PE - Perù 10
IE - Irlanda 9
EU - Europa 8
IL - Israele 8
JO - Giordania 8
KE - Kenya 8
MY - Malesia 8
TW - Taiwan 8
AU - Australia 7
IR - Iran 7
LT - Lituania 7
RO - Romania 7
TN - Tunisia 7
KZ - Kazakistan 6
AE - Emirati Arabi Uniti 5
AZ - Azerbaigian 5
DO - Repubblica Dominicana 5
DZ - Algeria 5
OM - Oman 5
BB - Barbados 4
ET - Etiopia 4
NG - Nigeria 4
PA - Panama 4
PT - Portogallo 4
SV - El Salvador 4
TH - Thailandia 4
UY - Uruguay 4
CR - Costa Rica 3
NO - Norvegia 3
NP - Nepal 3
PS - Palestinian Territory 3
PY - Paraguay 3
RS - Serbia 3
SN - Senegal 3
TJ - Tagikistan 3
AL - Albania 2
AO - Angola 2
BG - Bulgaria 2
BO - Bolivia 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
GE - Georgia 2
HR - Croazia 2
KH - Cambogia 2
KW - Kuwait 2
LV - Lettonia 2
MN - Mongolia 2
NZ - Nuova Zelanda 2
SI - Slovenia 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
BA - Bosnia-Erzegovina 1
CM - Camerun 1
CY - Cipro 1
DJ - Gibuti 1
DK - Danimarca 1
Totale 188.321
Città #
Cagliari 167.475
Uta 3.886
Fairfield 1.013
Ashburn 858
Woodbridge 732
Singapore 731
Chandler 594
Dallas 495
San Jose 471
Houston 439
Ann Arbor 396
Seattle 370
Wilmington 356
Cambridge 352
Boardman 324
Beijing 312
Nyköping 289
New York 250
Jacksonville 248
Council Bluffs 213
Dearborn 193
Santa Clara 141
Los Angeles 136
Hong Kong 131
Nanjing 113
Helsinki 112
The Dalles 107
Shanghai 106
Lauterbourg 98
Ho Chi Minh City 97
Boston 93
Hangzhou 93
Dong Ket 68
Hefei 59
Hanoi 57
Buffalo 54
Seoul 52
San Diego 50
Munich 44
Guangzhou 42
Milan 40
Shenyang 35
São Paulo 34
Toronto 33
Frankfurt am Main 32
London 31
Brooklyn 30
Chicago 29
Redondo Beach 29
Norwalk 27
Rome 27
Tianjin 26
Nanchang 25
Redwood City 25
Columbus 24
Orem 24
Tokyo 24
Falls Church 23
Hebei 22
Phoenix 22
Sassari 20
Atlanta 19
Da Nang 19
Mexico City 19
Montreal 19
Warsaw 19
Changsha 18
Chennai 18
Sestu 18
Cracow 17
Washington 17
Haiphong 16
Mountain View 16
Verona 15
Brussels 14
Jinan 14
Tashkent 14
Amsterdam 13
Jiaxing 13
Ningbo 13
San Francisco 13
Zhengzhou 13
Curitiba 12
Dhaka 12
Orange 12
Padova 12
Wuhan 12
Alexandria 11
Johannesburg 11
Lappeenranta 11
Miami 11
Manchester 10
New Delhi 10
Nuremberg 10
Rio de Janeiro 10
Auburn Hills 9
Baghdad 9
Belo Horizonte 9
Brasília 9
Casablanca 9
Totale 182.758
Nome #
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease 4.300
Pharmacological characterization of 50-kHz ultrasonic vocalizations in rats: comparison of the effects of different psychoactive drugs and relevance in drug-induced reward 3.660
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease 3.553
Widespread reduction of dopamine cell bodies and terminals in adult rats exposed to a low dose regimen of MDMA during adolescence 3.486
Strain dependence of adolescent Cannabis influence on heroin reward and mesolimbic dopamine transmission in adult Lewis and Fischer 344 rats 3.385
Role of Adenosine in the basal Ganglia 3.371
The novel psychoactive substance methoxetamine induces persistent behavioral abnormalities and neurotoxicity in rats 3.178
Antagonism of Adenosine A1 or A2A Receptors Amplifies the Effects of 3,4-Methylendioxymethamphetamine (MDMA) on Glial Activation in the Mouse Brain: Relevance to Caffeine-MDMA Interactions 3.136
Dopaminergic neurodegeneration in a rat model of long-term hyperglycemia: preferential degeneration of the nigrostriatal motor pathway 3.032
Elevation of striatal urate in experimental models of Parkinson's disease: a compensatory mechanism triggered by dopaminergic nigrostriatal degeneration? 3.023
Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms 2.977
Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists 2.950
Direct and long-lasting effects elicited by repeated drug administration on 50-kHz ultrasonic vocalizations are regulated differently: Implications for the study of the affective properties of drugs of abuse 2.856
Modulation of rat 50-kHz ultrasonic vocalizations by glucocorticoid signaling: possible relevance to reward and motivation 2.844
Role of adenosine A2A receptors in motor control: relevance to Parkinson’s disease and dyskinesia 2.789
Effect of crowding, temperature and age on glia activation and dopaminergic neurotoxicity induced by MDMA in the mouse brain 2.737
Methylxanthines and drug dependence: interactions and toxicity 2.715
Symptomatic and Neuroprotective Effects of A2A Receptor Antagonists in Parkinson’s Disease 2.693
Amphetamine usage, misuse, and addiction processes: an overview 2.651
Neuronal and peripheral damages induced by synthetic psychoactive substances: an update of recent findings from human and animal studies 2.636
Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility 2.552
Progression and Persistence of Neurotoxicity Induced by MDMA in Dopaminergic Regions of the Mouse Brain and Association with Noradrenergic, GABAergic, and Serotonergic Damage 2.537
Repeated Administration of 3,4-Methylenedioxymethamphetamine (MDMA) Elevates the Levels of Neuronal Nitric Oxide Synthase in the Nigrostriatal System: Possible Relevance to Neurotoxicity 2.536
Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l-DOPA-induced rotational behavior in a rodent model of Parkinson's disease 2.535
Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease 2.527
Influence of dopamine transmission in the medial prefrontal cortex and dorsal striatum on the emission of 50-kHz ultrasonic vocalizations in rats treated with amphetamine: Effects on drug-stimulated and conditioned calls 2.526
Involvement of Glutamate NMDA Receptors in the Acute, Long-Term, and Conditioned Effects of Amphetamine on Rat 50kHz Ultrasonic Vocalizations 2.444
Activation of adenosine A2A receptors suppresses the emission of pro-social and drug-stimulated 50-kHz ultrasonic vocalizations in rats: possible relevance to reward and motivation 2.410
Gut Microbiota and Metabolome Alterations Associated with Parkinson’s Disease 2.382
L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies 2.356
MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex 2.283
Contribution of Caffeine to the Psychostimulant, Neuroinflammatory and Neurotoxic Effects of Amphetamine-Related Drugs 2.238
Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons 2.133
Neurophysiological and Neurochemical Effects of the Putative Cognitive Enhancer (S)-CE-123 on Mesocorticolimbic Dopamine System 2.132
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug 2.114
Emission of categorized 50-kHz ultrasonic vocalizations in rats repeatedly treated with amphetamine or apomorphine: possible relevance to drug-induced modifications in the emotional state 2.114
Repeated amphetamine administration and long-term effects on 50-kHz ultrasonic vocalizations: possible relevance to the motivational and dopamine-stimulating properties of the drug 1.994
Preface [ to The Adenosinergic System. A Non-Dopaminergic Target in Parkinson’s Disease] 1.991
Role of movement in long-term basal ganglia changes: implications for abnormal motor responses 1.977
Ultrasonic vocalizations as a tool in studying emotional states in rodent models of social behavior and brain disease 1.931
Alteration in the progression of dopamine neuron degeneration: May caffeine offer new perspective? 1.892
Gender Differences in Neurodegeneration, Neuroinflammation and Na+-Ca2+ Exchangers in the Female A53T Transgenic Mouse Model of Parkinson’s Disease 1.850
Increased emissions of 50-kHz ultrasonic vocalizations in hemiparkinsonian rats repeatedly treated with dopaminomimetic drugs: A potential preclinical model for studying the affective properties of dopamine replacement therapy in Parkinson's disease 1.836
Unbinding of Translocator Protein 18 kDa (TSPO) Ligands: From in Vitro Residence Time to in Vivo Efficacy via in Silico Simulations 1.826
Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions 1.811
Caffeine consumption and changes in the function of dopaminergic transmission: evidence of a hyperdopaminergic state in rats subchronically treated with caffeine 1.801
Pharmacological therapy of Parkinson's disease: current options and new avenues 1.786
Repertoire and Biological Function of Ultrasonic Vocalizations in Adolescent and Adult Rats 1.722
null 1.722
Effect of long-term administration of antiretroviral drugs (Tenofovir and Nevirapine) on neuroinflammation and neuroplasticity in mouse hippocampi 1.689
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat 1.662
null 1.651
Effects of Psychostimulants on Rat Emotional States and Emission of Ultrasonic Vocalizations 1.546
The sweet road to Parkinson's disease 1.529
Diabetes, a Contemporary Risk for Parkinson’s Disease: Epidemiological and Cellular Evidences 1.493
Ultrasonic vocalizations in rats: a tool for the investigation of psychoactive drugs and neuropsychiatric conditions 1.479
Adenosine A2A receptors: localization and function 1.478
Gender specific reduction of hypermotility by sub-chronic methylphenidate or atomoxetine in SH rats, an animal model of ADHD 1.442
Rat 50-kHz ultrasonic vocalizations as a tool in studying neurochemical mechanisms that regulate positive emotional states 1.413
Adenosine signaling in the basal ganglia 1.311
Blockade of globus pallidus adenosine A2A receptors displays antiparkinsonian activity in 6-hydroxydopamine-lesioned rats treated with D1 or D2 dopamine receptor agonists 1.302
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats 1.293
Rat ultrasonic vocalizations and behavioral neuropharmacology: from the screening of drugs to the study of disease 1.263
Acute perinatal asphyxia impairs non-spatial memory and alters motor coordination in adult male rats 1.218
Neurochemical and Behavioral Characterization after Acute and Repeated Exposure to Novel Synthetic Cannabinoid Agonist 5-MDMB-PICA 1.205
null 1.194
The 6-hydroxydopamine model of Parkinson's disease 1.193
Anti-HIV drugs promote β-amyloid deposition and impair learning and memory in BALB/c mice 1.193
Adenosine A2A receptor antagonist treatment of Parkinson’s disease 1.146
In utero exposure to dexamethasone causes a persistent and age-dependent exacerbation of the neurotoxic effects and glia activation induced by MDMA in dopaminergic brain regions of C57BL/6J mice 1.144
Adenosine A2A receptor antagonists and Parkinson’s disease: state of the art and future directions 1.142
A2A receptor antagonism and dyskinesia in Parkinson’s Disease 1.116
null 1.108
Caffeine Consumption and Changes in the Function of Dopaminergic Transmission: Evidence of a Hyperdopaminergic State in Rats Subchronically Treated with Caffeine 1.094
Perinatal asphyxia: CNS development and deficits with delayed onset 1.046
Repeated exposure to JWH-018 induces adaptive changes in the mesolimbic and mesocortical dopamine pathways, glial cells alteration and behavioural correlates 1.040
The Intranigral Infusion of Human-Alpha Synuclein Oligomers Induces a Cognitive Impairment in Rats Associated with Changes in Neuronal Firing and Neuroinflammation in the Anterior Cingulate Cortex 1.036
Methylxanthines and Drug Dependence: A Focus on Interactions with Substances of Abuse 1.035
Anxyiolytic properties of a 2-phenylindolglyoxylamide TSPO ligand: Stimulation of in vitro neurosteroid production affecting GABAA receptor activity 1.035
null 1.012
Activation of Antioxidant and Proteolytic Pathways in the Nigrostriatal Dopaminergic System After 3,4-Methylenedioxymethamphetamine Administration: Sex-Related Differences 1.009
Protective Agents in Parkinson’s Disease: Caffeine and Adenosine A2A Receptor Antagonists 971
null 967
Lack of drug- and cue-stimulated emissions of ultrasonic vocalizations in C57BL/6 J mice repeatedly treated with amphetamine 965
Perinatal asphyxia: current status and approaches towards neuroprotective strategies, with focus on sentinel proteins 942
Priming of rotational behavior by a dopamine receptor agonist in hemiparkinsonian rats: Movement-dependent induction 926
What do you see as the main priorities, Opportunities, and Challenges in Caffeine Research in the Next Five Years? 898
Association between novel object recognition/spontaneous alternation behavior and emission of ultrasonic vocalizations in rats: Possible relevance to the study of memory 882
Effects of combination antiretroviral drugs (cART) on hippocampal neuroplasticity in female mice 879
Acute and long-term effects elicited by psychoactive drugs on 50-kHz ultrasonic vocalizations in rats: development of a new experimental tool for the study of drug-mediated reward. 809
Caffeine 784
Nicotinamide prevents the long-term effects of perinatal asphyxia on apoptosis, non-spatial working memory and anxiety in rats 783
Editorial of special issue – Synthetic psychoactive substances and neurological diseases: Toxic and therapeutic effects 756
Can dietary substances protect against Parkinson's disease? The case of caffeine 741
null 685
Increase of dopamine D2(High) receptors in the striatum of rats sensitized to caffeine motor effects 653
Influence of acute caffeine on 50-kHz ultrasonic vocalizations in male adult rats and relevance to caffeine-mediated psychopharmacological effects 620
Dopaminergic Treatments for Parkinson’s Disease: Light and Shadows 598
Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis 596
null 594
Totale 179.496
Categoria #
all - tutte 241.166
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 241.166


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20229.320 0 719 656 770 740 687 720 604 759 1.075 1.110 1.480
2022/202317.432 1.649 2.449 1.978 1.467 1.488 1.707 837 1.260 1.134 1.264 1.513 686
2023/202415.716 713 740 548 865 1.643 2.554 2.484 1.094 709 1.113 1.602 1.651
2024/202523.526 4.557 4.795 3.957 3.215 1.708 1.964 2.040 165 355 273 309 188
2025/20268.812 776 356 893 658 729 539 1.830 543 499 1.002 492 495
2026/2027625 298 327 0 0 0 0 0 0 0 0 0 0
Totale 189.075